<DOC>
	<DOCNO>NCT00006353</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know radiation therapy effective without temozolomide glioblastoma multiforme . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy without temozolomide treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Radiation Therapy With Without Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy radiotherapy without temozolomide term overall survival patient newly diagnose glioblastoma multiforme . II . Compare toxicity profile regimens patient . III . Compare progression free survival patient treat regimen . IV . Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , age ( 50 vs 50 ) , WHO/ECOG performance status ( 0-1 v 2 ) , extent surgical resection ( biopsy v complete incomplete resection ) . Patients randomize one two treatment arm . Arm I : Patients undergo radiotherapy 5 day week 6 week . Arm II : Patients undergo radiotherapy arm I concurrently oral temozolomide daily 6 week . Patients receive adjuvant oral temozolomide alone day 1-5 every 28 day 6 course begin 4 week completion radiotherapy . Quality life assess prior study , week 4 radiotherapy , 4 week completion radiotherapy , end course 3 6 adjuvant chemotherapy ( arm II ) , every 3 month disease progression . Patients follow every 3 month disease progression death . PROJECTED ACCRUAL : A total 520 patient ( 260 per treatment arm ) accrue study within 3.5 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose glioblastoma multiforme biopsy surgical resection Grade IV disease Initial diagnosis great 6 week prior study PATIENT CHARACTERISTICS : Age : 18 70 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT less 2.5 time ULN Alkaline phosphatase less 2.5 time ULN No chronic hepatitis B C Renal : Creatinine great 1.5 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known HIV infection No medical condition would interfere oral medication intake ( e.g. , frequent vomit partial bowel obstruction ) No prior concurrent malignancy except surgically cure carcinoma situ cervix nonmelanoma skin cancer No serious medical , psychological , familial , sociological , geographical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent filgrastim ( GCSF ) , sargramostim ( GMCSF ) , epoetin alfa No concurrent biologic therapy No concurrent immunotherapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 14 day prior corticosteroid stable dose require Concurrent corticosteroid allow Radiotherapy : No prior radiotherapy No concurrent stereotactic boost radiotherapy Surgery : See Disease Characteristics No concurrent surgery tumor debulking Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>